AT13148
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.
Product Specifications
CAS Number
1056901-62-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; PKA; Ribosomal S6 Kinase (RSK) ; ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/at13148.html
Purity
99.20
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
ClC1=CC=C([C@](C2=CC=C(C3=CNN=C3)C=C2)(O)CN)C=C1
Molecular Formula
C17H16ClN3O
Molecular Weight
313.78
Precautions
H302, H315, H319, H335
References & Citations
[1]Yap TA, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18 (14) :3912-23.|[2]Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016 Sep 9;478 (1) :330-6
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Akt1; Akt2; Akt3; p70S6K; PKA; ROCK1; ROCK2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-H121133-25MG 25 mg
2-Hydroxy-6-(4-hydroxyphenethyl)-benzoic acid-13C6
Sign In for Pricing
View Details 
